Sergio Matarraz

Centro de Investigación del Cáncer

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

AÓ

Alberto Órfão

Centro de Investigación Biomédica en Red de Cáncer

Dolores Subirá

Hospital Universitario de Guadalajara

Vincent H. J. van der Velden

Erasmus MC

Jacques J. M. van Dongen

Leiden University Medical Center

Katherina Psarra

Evangelismos Hospital

Ulrika Johansson

University Hospitals Bristol NHS Foundation Trust

Peter Bettelheim

Krankenhaus der Elisabethinen

Wolfgang Kern

Munich Leukemia Laboratory (Germany)

Matteo Giovanni Della Porta

IRCCS Humanitas Research Hospital

Theresia M. Westers

Vrije Universiteit Amsterdam

Cooperative Institutions

Universidad de Salamanca

114

Instituto de Investigación Biomédica de Salamanca

109

Centro de Investigación del Cáncer

105

Centro de Investigación Biomédica en Red de Cáncer

Massachusetts General Hospital

Instituto de Salud Carlos III

Leiden University Medical Center

Complejo Hospitalario de Salamanca

Consejo Superior de Investigaciones Científicas

Clinica Universidad de Navarra

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features

Haematologica (2010)

Martin Schmidt‐Hieber Martín Pérez‐Andres Bruno Paiva Juan Flores‐Montero Juan J. Pérez

Aberrant CD117 expression is associated with a favorable outcome in multiple myeloma. We analyzed 106 patients with symptomatic multiple myeloma (n=50), smoldering multiple myeloma (n=38) and monoclonal gammopathy of undetermined significance (n=18) to elucidate biological features of CD117+ versus CD117− monoclonal gammopathies. CD117+ (mono)clonal plasma cells were detected in 30% symptomatic multiple myeloma, 45% smoldering multiple myeloma and 72% monoclonal gammopathy of undetermined significance patients. CD117 expression was associated with higher percentages of normal bone marrow plasma cells, CD117+ myeloid precursors and CD38+ B lymphocytes in all monoclonal gammopathies. Conversely, the number of bone marrow CD34+ myeloid cells and peripheral blood neutrophils was reduced among CD117+ multiple myeloma but not monoclonal gammopathy of undetermined significance patients.CD117 expression by (mono)clonal plasma cells is associated with uniquely altered patterns of production of hematopoietic bone marrow cells with decreased peripheral blood neutrophil counts and persistence of normal residual bone marrow plasma cells.

CD117

10.3324/haematol.2010.031872

Cite

Citations (52)

Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia

Haematologica (2023)

Cristina Bugarin Laura Antolini Chiara Buracchi Sergio Matarraz Tiziana Coliva

Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and follow-up of hematological malignancies, nevertheless it is not routinely used for JMML diagnosis. Herewith, we characterized the CD34+ hematopoietic precursor cells collected from 31 children with JMML using a combination of standardized EuroFlow antibody panels to assess the ability to discriminate JMML cells from normal/reactive bone marrow cell as controls (n=29) or from cells of children with other hematological diseases mimicking JMML (n=9). CD34+ precursors in JMML showed markedly reduced B-cell and erythroid-committed precursors compared to controls, whereas monocytic and CD7+ lymphoid precursors were significantly expanded. Moreover, aberrant immunophenotypes were consistently present in CD34+ precursors in JMML, while they were virtually absent in controls. Multivariate logistic regression analysis showed that combined assessment of the number of CD34+CD7+ lymphoid precursors and CD34+ aberrant precursors or erythroid precursors had a great potential in discriminating JMMLs versus controls. Importantly our scoring model allowed highly efficient discrimination of truly JMML versus patients with JMML-like diseases. In conclusion, we show for the first time that CD34+ precursors from JMML patients display a unique immunophenotypic profile which might contribute to a fast and accurate diagnosis of JMML worldwide by applying an easy to standardize single eight-color antibody combination.

Juvenile myelomonocytic leukemia

Immunophenotyping

10.3324/haematol.2023.282805

Cite

Citations (1)

Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis

Leukemia (2013)

Carlos Fernández Maria Cláudia Santos‐Silva Antonio López Sergio Matarraz María Jara‐Acevedo

Myelopoiesis

Minimal Residual Disease

Immunophenotyping

10.1038/leu.2013.109

Cite

Citations (13)

P-142 The proliferation index of bone marrow cells from myelodysplastic syndromes is associated with the diagnostic and prognostic of the disease

Leukemia Research (2013)

Sergio Matarraz Cristina Teodósio C Fernández Manuel Albors María Jara‐Acevedo

Decitabine

Azacitidine

Idarubicin

10.1016/s0145-2126(13)70190-5

Cite

Citations (0)

Quantitative analysis of the expression of glycosylphosphatidylinositol‐anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow

Cytometry Part B Clinical Cytometry (2006)

Pilar Hernández-Campo Júlia Almeida Sergio Matarraz M. de Jesús Gallegos Santiago María Luz Sánchez

Abstract Background: Glycosylphosphatidylinositol‐anchored proteins (GPI‐AP) are a heterogeneous group of proteins deficiently expressed in patients with paroxysmal nocturnal hemoglobinuria. Up till now, no study has been reported in which the exact patterns of expression of a large number of GPI‐AP are quantitatively evaluated in normal bone marrow (BM) cells classified according to their lineage and maturation stage. Methods: In the present study, we have quantitatively analyzed the expression of eleven different GPI‐AP (CD14, CD16, CD24, CD48, CD52, CD58, CD59, CD66b, CD87, CD109 and CD157) during maturation of the neutrophil, monocytic, erythroid, lymphoid, basophil and plasmacytoid dendritic cells (DC) lineages in normal BM as a frame of reference for the understanding of the abnormal patterns of expression of GPI‐AP observed in the BM of PNH patients. Results: Our results show that expression of most GPI‐AP varies during normal BM maturation, different profiles being frequently observed depending on the cell lineage or the GPI‐AP analyzed. Conclusion: Overall, these results provide a detailed map GPI‐AP expression during normal hematopoietic differentiation, which could serve as a basis for the identification and characterization of changes occurring in PNH. © 2006 International Society for Analytical Cytology

Paroxysmal nocturnal hemoglobinuria

Lineage (genetic)

CD59

10.1002/cyto.b.20143

Cite

Citations (64)

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group

Cytometry Part B Clinical Cytometry (2021)

Arjan A. van de Loosdrecht Wolfgang Kern Anna Porwit Peter Valent Shahram Kordasti

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Cytopenia

10.1002/cyto.b.22044

Cite

Citations (27)

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

Leukemia (2014)

Anna Porwit Arjan A. van de Loosdrecht Peter Bettelheim Lisa Eidenschink Brodersen Kate Burbury

Work flow

Working group

10.1038/leu.2014.191

Cite

Citations (135)

Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study

Cancers (2022)

Nienke Brouwer Sergio Matarraz Stefan Nierkens Mattias Hofmans Michaela Nováková

Acute megakaryoblastic leukemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukemia (AML). We evaluated the immunophenotypic profile of 72 AMKL and 114 non-AMKL AML patients using the EuroFlow AML panel. Univariate and multivariate/multidimensional analyses were performed to identify most relevant markers contributing to the diagnosis of AMKL. AMKL patients were subdivided into transient abnormal myelopoiesis (TAM), myeloid leukemia associated with Down syndrome (ML-DS), AML-not otherwise specified with megakaryocytic differentiation (NOS-AMKL), and AMKL-other patients (AML patients with other WHO classification but with flowcytometric features of megakaryocytic differentiation). Flowcytometric analysis showed good discrimination between AMKL and non-AMKL patients based on differential expression of, in particular, CD42a.CD61, CD41, CD42b, HLADR, CD15 and CD13. Combining CD42a.CD61 (positive) and CD13 (negative) resulted in a sensitivity of 71% and a specificity of 99%. Within AMKL patients, TAM and ML-DS patients showed higher frequencies of immature CD34+/CD117+ leukemic cells as compared to NOS-AMKL and AMKL-Other patients. In addition, ML-DS patients showed a significantly higher expression of CD33, CD11b, CD38 and CD7 as compared to the other three subgroups, allowing for good distinction of these patients. Overall, our data show that the EuroFlow AML panel allows for straightforward diagnosis of AMKL and that ML-DS is associated with a unique immunophenotypic profile.

Acute megakaryoblastic leukemia

CD117

GATA1

Univariate analysis

Immunophenotyping

10.3390/cancers14061583

Cite

Citations (20)

Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low‐risk myelodysplastic syndrome. Is it feasible?

Cytometry Part B Clinical Cytometry (2017)

Patricia Font Dolores Subirá Sergio Matarraz Celina Benavente María‐Teresa Cedena

Accuracy of bone marrow (BM) blast count in low-risk myelodysplastic syndromes (MDS) still remains a challenge though it is essential for prognosis. We investigated whether the enumeration of CD34+ myeloid cells by flow cytometry immunophenotyping (FCI) could be used as a consistent parameter for clinical MDS studies.Six clinical centers entered the study and information on their FCI protocols was recorded. Sixty-seven flow cytometry listmodes from BM samples of patients with low-risk MDS with <5% BM blasts were exchanged among participants in two different rounds. Interlaboratory variations on the quantification of CD34+ myeloid cells were calculated and strategies to solve differences were evaluated.An overall "very good" agreement on CD34+ cell count among participants (intraclass correlation coefficient = 0.720) was observed, but agreement was "low" in 22 files. No single parameter could fully explain all discrepancies, but 3 technical issues were identified as relevant: the use of the CD34/CD45/CD117/HLA-DR mAb combination, acquisition of ≥50,000 events and a low percentage of debris/aggregates. The frequency of discordant results increased with the accumulation of pitfalls (none, 16%; 1 pitfall, 40%; 2 pitfalls, 83%; P = 0.006). Finally, the use of a common gating strategy for analysis increased the percentage of files with "very good" agreement to 100%.Prevention of specific technical pitfalls is mandatory to reach a good reproducibility of CD34+ cell count among centers. These recommendations set the basis for laboratory standardization and enable the use of CD34+ cell enumeration as additional information in low-risk MDS patients. © 2017 International Clinical Cytometry Society.

Immunophenotyping

CD117

Enumeration

10.1002/cyto.b.21538

Cite

Citations (12)

New technologies in cancer. Protein microarrays for biomarker discovery

Clinical & Translational Oncology (2011)

Sergio Matarraz María González‐González María Jara‐Acevedo Alberto Órfão Manuel Fuentes

Biomarker Discovery

Protein microarray

Cancer Biomarkers

10.1007/s12094-011-0635-8

Cite

Citations (37)